{
  "id": 3725569,
  "title": "Natera Partners With Angiex For CtDNA Monitoring In Solid Tumor Trial Using Signatera",
  "url": "https://urgent.news/2026/08/27/natera-partners-with-angiex-for-ctdna-monitoring-in-solid-tumor-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-27T10:56:31.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/natera-partners-angiex-ctdna-monitoring-solid-tumor-trial-using-signatera"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Natera, Inc. (NTRA), a clinical genetic testing company announced on Thursday that it will collaborate with privately held Angiex, Inc., to use its Signatera test for circulating tumor DNA monitoring in a Phase I study of AGX101, an investigational nuclear-delivered a",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}